Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
AcroCyte Therapeutics logo — 1 cell, to save lives

AcroCyte Therapeutics

1 cell, to save lives

Taiwan Taiwan 12 employees Series Unknown Biotechnology

General Information

Company Name AcroCyte Therapeutics
Location Taiwan Taiwan +1
Employees 12
Industries Biotechnology
Funding Stage Series Unknown
Social

Get notified when AcroCyte Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About AcroCyte Therapeutics

AcroCyte Therapeutics is a biotechnology startup based in Taiwan, specializing in cell-based precision medicine. The company's proprietary technology, R3CE (rapid, reproducible, rare cell expansion), enables 3D cell culture from any specimen within 2 weeks, even with extremely rare cells, offering potential for significant advancements in clinical treatment and scientific research. With a strong emphasis on integrating 3D cell culture and medicine, AcroCyte Therapeutics aims to revolutionize the field of precision medicine and ultimately, save lives. Their recent Venture Round investment on 01 February 2023 was led by Darwin Venture Management. AcroCyte Therapeutics' compelling mission and innovative technology have attracted support from investors, positioning the company for potential growth and influence in the biotechnology and precision medicine sectors. As a forward-thinking company with a dedicated team of scientists, industry leaders, and entrepreneurs, AcroCyte Therapeutics is poised to make a meaningful impact in the realm of precision medicine.

Taxonomy: precision medicine, cell-based therapy, 3D cell culture, rare cell expansion, clinical treatment, scientific research, cell proliferation, medicine innovation

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round •••••• 1
Investor
01 Feb 2023

AcroCyte Therapeutics Alternatives & Competitors

AcroCyte Therapeutics vs
PL BioScience GmbH
PL BioScience GmbH Germany

Xeno-Free Human Platelet Lysate Experts for Cell Therapy & GMP Manufacturing | Home of the ELAREM™ P...

Series A
33 employees
Biotechnology, Health Care
AcroCyte Therapeutics vs
Aglaris Ltd Group
Aglaris Ltd Group United Kingdom

Aglaris Ltd. together with Aglaris Cell, Changing Cellular Manufacturing: More productive, more reli...

Grant
11 employees
Biotechnology, Health Care
AcroCyte Therapeutics vs
CytoNest, Inc.
CytoNest, Inc. United States

Cell nesting technologies

7 employees
Biotechnology, Life Sciences

FAQ About AcroCyte Therapeutics

1 cell, to save lives
AcroCyte Therapeutics is headquartered in Taiwan.
AcroCyte Therapeutics operates in the following industries: Biotechnology.
AcroCyte Therapeutics has approximately 12 employees.
AcroCyte Therapeutics has completed 1 funding round. The latest funding stage is Series Unknown.
Top alternatives and competitors to AcroCyte Therapeutics include PL BioScience GmbH, Aglaris Ltd Group, CytoNest, Inc., Kangstem Biotech Co., Ltd., RareCyte, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
AcroCyte Therapeutics and PL BioScience GmbH are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors AcroCyte Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes